Edwards Lifesciences Corp (EW) - Net Assets
Based on the latest financial reports, Edwards Lifesciences Corp (EW) has net assets worth $10.33 Billion USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($13.32 Billion) and total liabilities ($2.99 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Edwards Lifesciences Corp to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $10.33 Billion |
| % of Total Assets | 77.53% |
| Annual Growth Rate | 8.55% |
| 5-Year Change | 77.14% |
| 10-Year Change | 294.72% |
| Growth Volatility | 19.53 |
Edwards Lifesciences Corp - Net Assets Trend (1999–2025)
This chart illustrates how Edwards Lifesciences Corp's net assets have evolved over time, based on quarterly financial data. See Edwards Lifesciences Corp defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Edwards Lifesciences Corp (1999–2025)
The table below shows the annual net assets of Edwards Lifesciences Corp from 1999 to 2025. For live valuation and market cap data, see market cap of Edwards Lifesciences Corp.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $10.34 Billion | +2.73% |
| 2024-12-31 | $10.06 Billion | +49.76% |
| 2023-12-31 | $6.72 Billion | +15.72% |
| 2022-12-31 | $5.81 Billion | -0.50% |
| 2021-12-31 | $5.84 Billion | +27.58% |
| 2020-12-31 | $4.57 Billion | +10.27% |
| 2019-12-31 | $4.15 Billion | +32.09% |
| 2018-12-31 | $3.14 Billion | +4.87% |
| 2017-12-31 | $2.99 Billion | +14.35% |
| 2016-12-31 | $2.62 Billion | +4.63% |
| 2015-12-31 | $2.50 Billion | +14.22% |
| 2014-12-31 | $2.19 Billion | +40.55% |
| 2013-12-31 | $1.56 Billion | +5.40% |
| 2012-12-31 | $1.48 Billion | +10.57% |
| 2011-12-31 | $1.34 Billion | +2.27% |
| 2010-12-31 | $1.31 Billion | +12.98% |
| 2009-12-31 | $1.16 Billion | +31.76% |
| 2008-12-31 | $878.80 Million | +5.25% |
| 2007-12-31 | $835.00 Million | +11.42% |
| 2006-12-31 | $749.40 Million | +8.61% |
| 2005-12-31 | $690.00 Million | +9.86% |
| 2004-12-31 | $628.10 Million | -1.10% |
| 2003-12-31 | $635.10 Million | +17.74% |
| 2002-12-31 | $539.40 Million | +17.52% |
| 2001-12-31 | $459.00 Million | +4.32% |
| 2000-12-31 | $440.00 Million | -64.05% |
| 1999-12-31 | $1.22 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Edwards Lifesciences Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3306.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $14.24 Billion | 137.75% |
| Common Stock | $658.70 Million | 6.37% |
| Other Comprehensive Income | $-238.30 Million | -2.31% |
| Total Equity | $10.34 Billion | 100.00% |
Edwards Lifesciences Corp Competitors by Market Cap
The table below lists competitors of Edwards Lifesciences Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
UCB SA
BR:UCB
|
$49.68 Billion |
|
RIO Tinto Ltd
AU:RIO
|
$49.80 Billion |
|
Danone SA
PA:BN
|
$50.04 Billion |
|
NATWEST GROUP SP.ADR/2
F:RYS
|
$50.04 Billion |
|
Infosys Limited
NSE:INFY
|
$49.67 Billion |
|
Microchip Technology Inc
NASDAQ:MCHP
|
$49.53 Billion |
|
Old Dominion Freight Line Inc
NASDAQ:ODFL
|
$49.38 Billion |
|
Carvana Co
NYSE:CVNA
|
$49.35 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Edwards Lifesciences Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,998,400,000 to 10,337,600,000, a change of 339,200,000 (3.4%).
- Net income of 1,073,500,000 contributed positively to equity growth.
- Share repurchases of 893,400,000 reduced equity.
- Other comprehensive income increased equity by 6,200,000.
- Other factors increased equity by 152,900,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.07 Billion | +10.38% |
| Share Repurchases | $893.40 Million | -8.64% |
| Other Comprehensive Income | $6.20 Million | +0.06% |
| Other Changes | $152.90 Million | +1.48% |
| Total Change | $- | 3.39% |
Book Value vs Market Value Analysis
This analysis compares Edwards Lifesciences Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.89x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 49.14x to 4.89x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | $1.76 | $86.28 | x |
| 2000-12-31 | $0.63 | $86.28 | x |
| 2001-12-31 | $0.65 | $86.28 | x |
| 2002-12-31 | $0.73 | $86.28 | x |
| 2003-12-31 | $0.87 | $86.28 | x |
| 2004-12-31 | $0.84 | $86.28 | x |
| 2005-12-31 | $0.92 | $86.28 | x |
| 2006-12-31 | $0.98 | $86.28 | x |
| 2007-12-31 | $1.11 | $86.28 | x |
| 2008-12-31 | $1.23 | $86.28 | x |
| 2009-12-31 | $1.64 | $86.28 | x |
| 2010-12-31 | $1.83 | $86.28 | x |
| 2011-12-31 | $1.87 | $86.28 | x |
| 2012-12-31 | $2.08 | $86.28 | x |
| 2013-12-31 | $2.28 | $86.28 | x |
| 2014-12-31 | $3.37 | $86.28 | x |
| 2015-12-31 | $3.79 | $86.28 | x |
| 2016-12-31 | $4.01 | $86.28 | x |
| 2017-12-31 | $4.62 | $86.28 | x |
| 2018-12-31 | $4.90 | $86.28 | x |
| 2019-12-31 | $6.52 | $86.28 | x |
| 2020-12-31 | $7.24 | $86.28 | x |
| 2021-12-31 | $9.25 | $86.28 | x |
| 2022-12-31 | $9.30 | $86.28 | x |
| 2023-12-31 | $10.91 | $86.28 | x |
| 2024-12-31 | $16.68 | $86.28 | x |
| 2025-12-31 | $17.65 | $86.28 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Edwards Lifesciences Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.38%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.69%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 1.32x
- Recent ROE (10.38%) is below the historical average (15.27%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | 6.70% | 9.06% | 0.63x | 1.17x | $-40.40 Million |
| 2000 | -61.82% | -33.83% | 0.74x | 2.47x | $-316.00 Million |
| 2001 | -2.61% | -1.73% | 0.71x | 2.12x | $-57.90 Million |
| 2002 | 10.33% | 7.91% | 0.70x | 1.87x | $1.76 Million |
| 2003 | 12.44% | 9.18% | 0.78x | 1.73x | $15.49 Million |
| 2004 | 0.27% | 0.18% | 0.84x | 1.77x | $-61.11 Million |
| 2005 | 11.49% | 7.95% | 0.81x | 1.78x | $10.30 Million |
| 2006 | 17.41% | 12.58% | 0.83x | 1.66x | $55.56 Million |
| 2007 | 13.53% | 10.36% | 0.81x | 1.61x | $29.50 Million |
| 2008 | 14.67% | 10.41% | 0.88x | 1.59x | $41.02 Million |
| 2009 | 19.79% | 17.34% | 0.82x | 1.40x | $113.31 Million |
| 2010 | 16.66% | 15.07% | 0.82x | 1.35x | $87.18 Million |
| 2011 | 17.69% | 14.10% | 0.85x | 1.48x | $102.91 Million |
| 2012 | 19.82% | 15.43% | 0.86x | 1.50x | $145.27 Million |
| 2013 | 25.12% | 19.15% | 0.75x | 1.75x | $235.78 Million |
| 2014 | 37.01% | 34.92% | 0.66x | 1.61x | $591.96 Million |
| 2015 | 19.77% | 19.85% | 0.61x | 1.62x | $244.59 Million |
| 2016 | 21.74% | 19.22% | 0.66x | 1.72x | $307.60 Million |
| 2017 | 20.77% | 18.11% | 0.60x | 1.90x | $322.63 Million |
| 2018 | 23.00% | 19.40% | 0.70x | 1.70x | $408.16 Million |
| 2019 | 25.24% | 24.08% | 0.67x | 1.56x | $632.07 Million |
| 2020 | 18.00% | 18.77% | 0.61x | 1.58x | $365.97 Million |
| 2021 | 25.76% | 28.73% | 0.62x | 1.46x | $919.51 Million |
| 2022 | 26.21% | 28.28% | 0.65x | 1.43x | $941.23 Million |
| 2023 | 21.09% | 23.35% | 0.64x | 1.41x | $737.40 Million |
| 2024 | 41.75% | 76.75% | 0.42x | 1.31x | $3.17 Billion |
| 2025 | 10.38% | 17.69% | 0.44x | 1.32x | $39.74 Million |
Industry Comparison
This section compares Edwards Lifesciences Corp's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $194,100,906
- Average return on equity (ROE) among peers: -184.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Edwards Lifesciences Corp (EW) | $10.33 Billion | 6.70% | 0.29x | $49.68 Billion |
| Abbott Laboratories (ABT) | $1.87 Billion | 24.87% | 0.85x | $154.19 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $16.90 Million |
| Aethlon Medical Inc (AEMD) | $595.41K | -1222.01% | 1.90x | $2.63 Million |
| Acutus Medical Inc (AFIB) | $-225.81 Million | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.35 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $456.18K | -277.12% | 2.12x | $6.16 Million |
| Allurion Technologies, Inc. (ALUR) | $-77.98 Million | 0.00% | 0.00x | $7.07 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $7.63 Million | -202.23% | 0.23x | $4.54 Million |
| Artivion Inc (AORT) | $279.04 Million | 1.33% | 1.12x | $1.02 Billion |
| Apyx Medical Inc (APYX) | $71.26 Million | -27.65% | 0.19x | $192.62 Million |
About Edwards Lifesciences Corp
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to t… Read more